MedTrace Logo

Two Regimens of Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Localized Ewing Sarcoma Family of Tumors

NCT00618813 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2014-09-25

Study results available
· View outcomes & findings →

Summary

This clinical trial is studying the side effects of combination chemotherapy and to see how well they work in treating patients with newly diagnosed localized Ewing sarcoma family of tumors. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) and giving the drugs in different ways may kill more tumor cells.

Conditions

  • Ewing Sarcoma of Bone
  • Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor

Interventions

OTHER

radiation therapy

Undergo radiation therapy

OTHER

therapeutic conventional surgery

Undergo surgery

DRUG

etoposide

Given IV

DRUG

ifosfamide

Given IV

DRUG

doxorubicin hydrochloride

Given IV

DRUG

cyclophosphamide

Given IV

DRUG

vincristine sulfate

Given IV

DRUG

topotecan hydrochloride

Given IV

BIOLOGICAL

filgrastim

Given SC

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Children's Oncology Group

    lead NETWORK

Principal Investigators

  • Leo Mascarenhas, MD MS · Children's Oncology Group

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2010-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00618813 on ClinicalTrials.gov